4210 da and 1866 da Polypeptides as Potential Biomarkers of Liver Disease Progression in Hepatitis B Virus Patients

New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and hepatocellular carcinoma. Scientists determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus.